 A sense of cautious optimism is looming over the Street given the progress in the reopening of the U.S. economy, and while the recent uptick isnt necessarily indicative of a full recovery, its certainly a step forward. Against this backdrop, Wall Street pros argue that certain sectors are holding up substantially better than the rest, and within these areas, compelling plays can be found. Highlighting the biotech space, the pros say there are names that have not only received a lot of love from the analyst community, but also stand to deliver hefty returns through 2020 and beyond.Inspired by the pros, we used TipRanks database to pinpoint noteworthy biotech stocks. We found three that tick the boxes; each has amassed enough bullish calls to earn a Strong Buy consensus rating and offers up serious upside potential.Cytokinetics, Inc. CYTKHistorically, diseases related to heart failure have been treated the same way, but Cytokinetics is shaking things up. Unlike its peers, it focuses on normalizing muscle contractility rather than solely on volume or rate control. For this reason, several analysts believe this biotechs future is only going to get brighter.One of these analysts is Mizuho Securities Salim Syed. Speaking to CYTKs differentiated approach, he commented, In our view, theres good clinical evidence that its not just a theory. In this regard, the therapies that Cytokinetics is working on, beginning with its lead asset, omecamtiv mecarbil, have the potential to be foundational backbones and shift the broader treatment paradigm that really had its start decades ago.Given how common heart failure is in the U.S., with the condition affecting more than 6 million people, Syed argues that the possibility of a new treatment angle is extraordinary. Compare this to the prevalence of Alzheimers, which afflicts over 5 million people, and the significance of diseases that cause heart failure becomes clearer.On top of this, Syed points out that investor focus has locked in on a key upcoming catalyst. A data readout for omecamtiv mecarbil in the Phase 3 heart failure cardiovascular outcomes trial CVOT, GALACTIC-HF, is slated for the fourth quarter of 2020, with investors anxiously waiting to see if the therapy can reduce cardiovascular death and heart failure events.After conducting a deep and step-wise analysis of each parameter of the GALACTIC-HF trial design, looking at historical CVOTs, available regression data and other nuances, Syed believes the probability of success PoS is high. Overall, through our work, what seems to be a competitive clinically meaningful bar on the primary endpoint and also CV death alone is about a 15-20 relative risk reduction, and we believe that omecamtiv mecarbil may produce an 18-22 relative risk reduction on the primary endpoint with a similar number on CV death, which would likely be a win, he stated.With a 70 PoS, Syed estimates that worldwide end-user unadjusted sales could come in at 4.2 billion. Not to mention CYTK is using its contractility work to find solutions for indications in the skeletal muscle disease space like ALS and SMA.It should come as no surprise, then, that Syed decided to join the bulls. He initiated coverage with a Buy rating and 31 price target, implying upside potential in the shape of 88. To watch Syeds track record, click hereDoes the rest of the Street agree with Syed? As it turns out, they do. With 100 Street support, or 5 Buys to be exact, the message is clear: CYTK is a Strong Buy. At 26.60, the average price target puts the upside potential at 62.5. See Cytokinetics stock analysis on TipRanksKeros Therapeutics KROSLeading the way when it comes to understanding the role of the Transforming Growth Factor- β TGF- β family of proteins, which regulate red blood cell and platelet production as well as the growth, repair and maintenance of muscle and bone, Keros develops treatments for patients with hematologic and musculoskeletal disorders. Based on its strong pipeline of assets targeting TGF- β, Wall Street has high hopes for this biotech, which IPOd only a month ago.Writing for H.C. Wainwright, five-star analyst Andrew Fein told clients, As a pioneer in developing novel TGF- β targeted therapies, Keros is able to rapidly translate biological insights into drug candidates. Following strong IPO performance since last month, we believe components of Keros pipeline and platform remain underappreciated by the Street for multiple reasons.These reasons include the recent approval of Accelerons Reblozyl as it validates the clinical utility of TGF- β ligand traps in multiple hematologic diseases. Fein also points out that Keros lead protein therapeutic product candidate, KER-050, which was designed for use in patients with myelodysplastic syndromes MDS and myelofibrosis MF, is differentiated and even superior to Reblozyl. He backs up this claim by citing data in healthy volunteers that demonstrated favorable safety as well as PKPD.Looking at the MDS market, which is valued at 1.6 billion, Fein argues initial data from the Phase 2 study could inflect substantial value, while validating the platform as a whole. It also doesnt hurt that KER-050s opportunity in the MDS market can be viewed along with additional diseases caused by ineffective hematopoiesis and exhibiting anemia andor thrombocytopenia, including myelofibrosis MF and beta-thalassemia.If that wasnt enough, KROS also boasts promising earlier stage therapies. Both KER-047 and KER-012 have already seen encouraging results, and are supported by strong scientific rationale. This gives the company optionality in the near- to mid-term, in Feins opinion.Fein added, Led by industry veterans from Acceleron, the Keros team possesses not only the scientific know-how as related to creating TGF- β targeted therapies, but also deep insights into the clinical pathway for each of their drug candidates. As such, we view Keros as a true platform play that should continuously fuel its pipeline with highly differentiated assets to drive value in the long run.To this end, Fein kicked off his KROS coverage by putting a Buy recommendation and 50 price target on the stock. Should this target be met, a twelve-month gain of 72 could be in store. To watch Feins track record, click hereJudging by the consensus breakdown, other analysts are also impressed. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. The 41 average price target is less aggressive than Feins but it still leaves room for shares to surge 37.5 in the next year. See Keros stock analysis on TipRanksBlack Diamond Therapeutics BDTXUsing its technology platform thats focused on identifying previously-undrugged allosteric mutations, Black Diamond wants to stomp out cancer. As this technology allows it to identify more selective, orally-bioavailable compounds that can exhibit greater efficacy and better safety and tolerability than currently marketed drugs as well as agents in development, some members of the Street are betting on BDTX.H.C. Wainwrights Ram Selvaraju is doing just that. The five-star analyst notes that Black Diamond as a leader in the discovery and design of novel therapeutics aimed at allosteric mutations in well-known oncogenes, hitherto unaddressable with existing medications.Highlighting its Mutations-Allostery-Pharmacology MAP platform, Selvaraju said, MAP provides a unique edge in pinpointing previously undrugged mutations and prioritizing those with the greatest oncogenic potentiali.e., the highest propensity to cause and drive cancer... Black Diamond intends to position its molecules as safer and more potent, capable of rapid advancement via pathways established for precision medicines in oncology. These can be deployed across cancers regardless of tissue of origin to treat those patients carrying specific mutations.Selvarajus excitement isnt limited to BDTXs platform. Pointing to its most advanced pipeline candidate, BDTX-189, which is currently in a Phase 12 trial, MasterKey-01, designed to evaluate the molecule in patients with non-small cell lung cancer NSCLC, breast cancer and other solid tumors, the analyst likes what hes seeing. The candidate has already demonstrated high selectivity for allosteric HER2 mutations and exon 20 insertions in the HER2 and EGFR gene, which are known to cause cancerous cell creation. Thanks to its highly selective nature, Selvaraju thinks BDTX-189 will be able to produce more anti-tumor activity, as well as be safer and better tolerated.As a result, BDTX-189 could see peak total annual sales hit 2.5 billion by 2030 in the U.S. and Europe, but this only factors in NSCLC patients with exon 20 insertion mutations and HER2 allosteric mutations in breast cancer plus other solid tumors.Expounding on this, Selvaraju commented, In our view, the drug could be priced at 22,000 per monthover 260,000 per yeargiven pricing for other precision oncology drugs in the 20-30,000 per month range and pricing for tucatinib at over 18,000 per month for a larger patient population. We note that these markets constitute areas of high unmet medical need in which existing standard-of-care medications have already proven unsuccessful. We expect BDTX-189 to be deployed across tumor types, similar to drugs like Vitrakvi larotrectinib and Rozlytrek entrectinib but targeting larger patient groups overall.Based on all of the above, its no wonder Selvaraju started out his coverage of this biotech by publishing a Buy rating. His 53 price target coveys his confidence in BDTXs ability to climb 47 higher in the next year. To watch Selvarajus track record, click hereTurning now to the rest of the Street, other analysts are also bullish. 